WESTBOROUGH, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it will hold its first Investor and Analyst Symposium.
During this meeting, the company Management and members of its Scientific Advisory Board will provide more details on RXi’s current clinical development compound for the treatment of dermal scarring, RXI-109, as well as insights into the company's other research programs and their potential. "As mentioned on several occasions, RXi Pharmaceuticals will have the complete unblinded data of their two Phase 1 studies available around the middle of this year", said Dr. Geert Cauwenbergh, President and CEO of the Company. He added that, "At this Investor and Analyst Symposium, we expect to announce the formal transition of RXI-109 into a Phase 2 clinical development program, and also provide more detail on the indications and patient population we will target in our Phase 2 studies. In addition the company will also give an update on its other earlier stage programs, with special emphasis on the ophthalmologic applications of its game changing self delivering RNAi platform."
This event will be held on Friday July 12, 2013, from 11:00am to 2:00pm at the OTCQX Market Center, 304 Hudson Street, New York, NY. Registration is required to attend this event, please contact Tamara McGrillen at tmcgrillen@rxipharma.com or 508-929-3646. A live webcast of the presentation will be available on the “Investors” section of the Company's website, www.rxipharma.com. A replay of the presentation will be available for 90 days.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi’s first RNAi product candidate, RXI-109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012. For more information, please visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation’s products and technologies. Forward-looking statements about expectations and development plans of RXi’s products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
